Versuchen GOLD - Frei

DAM Capital bets on earnings stability

Mint Chennai

|

January 12, 2026

India’s only listed pure-play investment bank, DAM Capital Advisors Ltd, plans to deploy its capital reserves into recurring, fee-based businesses to reduce the inherent volatility of investment banking, managing director and chief executive Dharmesh Mehta told Mint.

- Agnidev Bhattacharyya agnidev.bhattacharya@livemint.com

DAM Capital bets on earnings stability

The firm will use cash reserves to build fee-based businesses: MD and CEO Dharmesh Mehta

While merchant banking remains the firm’s primary earnings driver, DAM Capital is evaluating asset-light ancillary services that require minimal capital deployment and limited balance-sheet risk to diversify its revenue base.

The Mumbai-based investment bank reported a cash balance of ₹287 crore as of the first half of the 2025-26 fiscal year. “A portion of this is required as working capital for the institutional equities business, but a part of it is also dry powder for potential ventures into businesses like alternative investment funds (AIFs), retail broking, and wealth management,” Mehta said.

“We will look at everything that generates fees without large cash burn or high balance-sheet risk. Wealth management today is a valuation-driven segment, not profits. For a new entrant, it requires significant upfront investment. We will build these businesses when we get the right team or the right platform at reasonable valuations.”

WEITERE GESCHICHTEN VON Mint Chennai

Mint Chennai

Mint Chennai

Lenskart wants artificial intelligence to test your eyes

It expects AI-enabled eye testing to become the default foundational layer of eyecare delivery

time to read

3 mins

January 13, 2026

Mint Chennai

Mint Chennai

More companies to take a hit as labour codes debut

Reworked gratuity and leave encashments spell additional expenses for India Inc

time to read

2 mins

January 13, 2026

Mint Chennai

HC lifts ban on Zydus cancer biosimilar till patent expiry

In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.

time to read

2 mins

January 13, 2026

Mint Chennai

Trump’s investigation of Powell is also a warning to the next Fed chair

The criminal investigation into Federal Reserve Chair Jerome Powell isn’t ultimately about the Fed’s headquarters, or Powell, or even interest rates.

time to read

3 mins

January 13, 2026

Mint Chennai

Mint Chennai

States flag Almont-Kid syrup as tests find contaminants

Syrup found ‘Not of Standard Quality’ with contaminants like toxic ethylene glycol

time to read

1 mins

January 13, 2026

Mint Chennai

Mint Chennai

India at 100: Our choices today will define the next two decades

India's 2047 ambition is not guaranteed but achievable if we address all the potential pitfalls along our development path

time to read

4 mins

January 13, 2026

Mint Chennai

Now, inheritance works without probate—but why it still matters

Heirs can now act on a valid will without court cases, easing delays and unlocking assets in undisputed cases

time to read

6 mins

January 13, 2026

Mint Chennai

Why VCs have a new deep-tech playbook

where fundraising starts to drag,\" said Chand.

time to read

1 min

January 13, 2026

Mint Chennai

TCS, HCLTech deliver Q3 revenue surprise

clearer.

time to read

2 mins

January 13, 2026

Mint Chennai

Mint Chennai

US productivity is rising and it risks warping monetary policy

America's neutral rate ought to be going up but will the Fed listen?

time to read

3 mins

January 13, 2026

Listen

Translate

Share

-
+

Change font size